On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola's employment with the Company by mutual agreement, effective immediately. The termination of Mr. Vendola's employment with the Company by mutual agreement is not due to any disagreement with the Company or the Company's Board of Directors on any matter relating to the Company's operations, policies or practices. Mai-Britt Zocca, the Company's Chief Executive Officer and President, will act as the Company's Principal Financial Officer.

On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company's Vice President of Finance, as its Chief Accounting Officer, effective immediately. In his capacity as Chief Accounting Officer, Mr. Burkavage will also assume the role of the Company's Principal Accounting Officer. Prior to joining the Company in 2021, Mr. Burkavage was Controller at Passage BIO, Inc. from 2020 to 2021, and Director of Financial Planning and Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.